Showing results (291-300 of 2,105) with videos related to
Sort By:
Pageof 211
CNS Drugs|April 12, 2018
ND0701, A Novel Formulation of Apomorphine for Subcutaneous Infusion, in Comparison to a Commercial Apomorphine Formulation: 28-Day Pharmacokinetic Study in Minipigs and a Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Relative BioavailabilityYuval Ramot, Abraham Nyska, Liat Adar, et al.CNS Drugs|May 9, 2018
Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimer's DiseasePatricia Del Cerro, Carolina Alquézar, Fernando Bartolomé, et al.CNS Drugs|November 16, 2017
Drug Safety Analysis in a Real-Life Cohort of Parkinson's Disease Patients with PolypharmacySaskia Müller-Rebstein, Claudia Trenkwalder, Jens Ebentheuer, et al.CNS Drugs|May 19, 2022
Antidrug Antibodies Against Biological Treatments for Multiple SclerosisPer Soelberg SorensenCNS Drugs|May 26, 2022
Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor ActivationFlaminia Coluzzi, Laura Rullo, Maria Sole Scerpa, et al.CNS Drugs|June 24, 2021
Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018Nahid Moradi, Sifat Sharmin, Charles Malpas, et al.CNS Drugs|May 28, 2022
CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging TreatmentWilliam Hong, Isabel Haviland, Elia Pestana-Knight, et al.CNS Drugs|June 1, 2022
Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight GainMadeline M Corrao, Leigh Anne NelsonCNS Drugs|March 21, 2018
A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD)Tim L Wigal, Jeffrey H Newcorn, Nelson Handal, et al.CNS Drugs|December 19, 2018
Alzheimer's Disease Clinical Trials: Moving Toward Successful PreventionMichael S Rafii, Paul S AisenPageof 211